Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT07384767
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Excision Margin
  • Mohs Micrographic Surgery

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Timolol 0.5% Ophthalmic Solution — DRUG
    Topical Timolol 0.5% solution will be applied to patients wounds in 2 cm intervals along the widest diameter of the wound daily for 12 weeks following their medical procedure.
  • Hydrogel of placebo — OTHER
    Hydrogel will be placed on the wound at 2 cm intervals along the widest diameter of the wound daily for 12 weeks following the patient's medical procedure.

Study Details

The purpose of this research study is to evaluate the efficacy and safety of topical timolol 0.5% for secondary intention wound healing following 1) Mohs micrographic surgery, 2) standard surgical excision, OR 3) electrodesiccation and curettage (ED\&C). Please note that healing by secondary intention refers to when a wound heals naturally without surgical closure. To evaluate the efficacy of topical timolol 0.5%, 220 participants will be recruited. Participants will be placed into one of two groups: The treatment group or the control group. 1. The treatment group will receive a topical timolol 0.5% solution, which will be applied to their wound daily for 12 weeks. 2. The control group will receive standard care with the addition of hydrogel, which will also be applied to their wound daily for 12 weeks. During this 12-week period, both groups will be required to upload photos of their wound healing to their MyChart account at weeks 3, 6, 9, and 12. These photos will be reviewed by the investigator to assess wound healing. Re-epithelialization and earlier complete wound healing will be compared between both groups to determine the efficacy of topical timolol 0.5% solution compared to the standard of care.

Key Dates

Start date
Jun 1, 2026
Status verified
Feb 2026
Primary completion
Sep 1, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
220 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Timolol
    The treatment group will receive a topical timolol 0.5% solution, which will be applied to their wound daily for 12 weeks.
  • Placebo Comparator: Hydrogel
    The control group will receive standard care with the addition of hydrogel, which will also be applied to their wound daily for 12 weeks.

Primary Outcome Measure

Area of Surgical Ulcer [ Time Frame: Baseline, week 3, week 6, week 9 and week 12 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
UC Davis Health- DermatologySacramentoCalifornia95816
Ted Jacob, MD
[email protected]
Salsala Nasim, BS
[email protected]
916-551-2636
Daniel Eisen, MD (PRINCIPAL_INVESTIGATOR)
VA Medical Center- SacramentoSacramentoCalifornia95655
Pooja Shet, BS
[email protected]
Rivkah Isseroff, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sacramento, CA

By research site
UC Davis Health- Dermatology· Sacramento, CAVA Medical Center- Sacramento· Sacramento, CA

Related Studies